VPAC1 inhibitors belong to a specific chemical class of compounds designed to modulate the activity of VPAC1, also known as vasoactive intestinal peptide receptor 1. VPAC1 is a G-protein coupled receptor that binds to vasoactive intestinal peptide (VIP) and plays important roles in various physiological processes, including neurotransmission, immune responses, and hormonal regulation. These inhibitors are carefully designed to selectively target VPAC1 and interfere with its cellular functions.
The mechanism of action of VPAC1 inhibitors typically involves binding to specific regions of VPAC1, disrupting its interactions with VIP or other proteins, and affecting downstream signaling pathways. By inhibiting VPAC1, these compounds may impact cellular responses mediated by VIP and modulate the physiological processes regulated by VPAC1. Researchers use VPAC1 inhibitors to study the functional roles of VPAC1 in different cellular contexts and to explore its ability as a research target. Understanding the structural characteristics and mechanisms of VPAC1 inhibitors is crucial for advancing knowledge in this area and may have broader implications for future research in neurotransmission, immune regulation, and hormonal signaling.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PACAP(6-38) | 137061-48-4 | sc-391136 sc-391136A | 500 µg 1 mg | $540.00 $932.00 | ||
PACAP(6-38) is a truncated form of PACAP that has been studied for its potential inhibitory effects on VPAC1. | ||||||